Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX)
(Delayed Data from NSDQ)
$0.98 USD
-0.02 (-1.99%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $0.98 0.00 (0.00%) 5:02 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BDRX 0.98 -0.02(-1.99%)
Will BDRX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BDRX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BDRX
Results of Annual General Meeting
Biodexa Shareholders Approve Key Resolutions
Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona
Biodexa Pharmaceuticals to announce 12 month data of Phase 2 trial of eRapa
Biodexa Pharmaceuticals files to sell 2.49B ordinary shares for holders